N-[(5-chlorothiophene-2-yl)sulfonyl]-N'-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)urea potassium salt | 936501-01-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-[(5-chlorothiophene-2-yl)sulfonyl]-N'-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)urea potassium salt
• 英文别名: potassium 1-(5-chlorothiophen-2-ylsulfonyl)-3-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenylcarbamoyl)amide；potassium [4-(6-chloro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea；potassium [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea；[(5-chlorothiophene-2-yl)sulfonylcarbamoyl]-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide potassium；[(5-chlorothiophene-2-yl)sulfonylcarbamoyl]-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amine potassium；Elinogrel potassium；potassium;(5-chlorothiophen-2-yl)sulfonyl-[[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]carbamoyl]azanide
• CAS: 936501-01-8
• 化学式: C₂₀H₁₄ClFN₅O₅S₂*K
• 分子量: 562.043
• InChiKey: PPADHTVWIWCEDE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.87
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  162
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-[(5-氯-2-噻吩)磺酰基]氨基甲酸乙酯 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 17.0h， 生成 N-[(5-chlorothiophene-2-yl)sulfonyl]-N'-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)urea potassium salt
  参考文献：
  名称：

  WO2008/137809

  摘要：

  公开号：

文献信息

• [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto
  申请人：Scarborough Robert

  公开号：US20120088736A1

  公开（公告）日：2012-04-12

  The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

  本发明提供了式（I）的新型磺酰脲化合物及其药学上可接受的衍生物、多晶形式和非晶形式。这些化合物在其各种形式下均为有效的血小板ADP受体抑制剂，可用于各种制药组合物中，并且特别有效于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病。本发明还提供了制备这些化合物和形式的方法，并用于在哺乳动物中预防或治疗血栓形成和与血栓形成相关的疾病，包括给予式（I）化合物或其药学上可接受的盐或形式的治疗有效量。
• INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR
  申请人：Gretler Daniel D.

  公开号：US20120009172A1

  公开（公告）日：2012-01-12

  The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.

  本发明提供了一种方法和组合物，通过给予式中化合物，可快速和可逆地抑制需要该类人体主体中的血小板聚集，该式中化合物为： 单独给予或与第二种药物联合使用，该第二种药物可以是阿司匹林或溶栓药物。
• [EN] PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF FORMULA (I), AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES, FORMES PHARMACEUTIQUES ET NOUVELLES FORMES DU COMPOSÉ DE FORMULE (I), ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2012072824A1

  公开（公告）日：2012-06-07

  The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2- ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)- yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof.

  本发明涉及一种新的晶体无水形式，即[(5-氯噻吩-2-基磺酰胺)-(4-(6-氟-7-(甲基氨基)-2,4-二氧杂喹啉-3(4H)-基)苯基)酰胺，钾盐，以及其在动物，特别是人类中用于治疗或预防具有血小板ADP受体抑制作用的疾病或疾病状态，特别是P2Y12抑制作用。本发明还涉及制备这种新的晶体形式的过程。本发明还涉及这种新的晶体形式的固体口服制剂，以及其制备和使用。
• WO2007/56167
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2008137809A2
  申请人：——

  公开号：——

  公开（公告）日：——